Scilex’s Semnur Pharmaceuticals to go public through $2.5B SPAC merger as it advances sciatica prospect
By Zoey Becker
In a deal announcement, Semnur Pharmaceuticals’ parent company touted the commercial potential of Semdexa for sciatica pain. (Getty Images)